Literature DB >> 15116294

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.

George L Drusano1, Sandra L Preston, Cynthia Fowler, Michael Corrado, Barbara Weisinger, James Kahn.   

Abstract

Our objective was to prospectively determine the factors influencing the probability of a good microbiological or clinical outcome in patients with nosocomial pneumonia treated with a fluoroquinolone. Levofloxacin was administered as an infusion of 500 mg/h for 1.5 h (total dose, 750 mg). For patients with Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus, a second drug was added (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicillin-resistant S. aureus). Population pharmacokinetic studies of 58 patients demonstrated that this population handled the drug differently from populations of volunteers. Multivariate logistic regression analysis (n=47 patients) demonstrated that only the age of the patient and the achievement of an area under the curve: minimum inhibitory concentration ratio of > or =87 had a significant effect on eradication of the pathogen (P<.001). Achieving the breakpoint made the patient 4 times more likely to achieve eradication. The effect was greatest in patients > or =67 years old.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116294     DOI: 10.1086/383320

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  69 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.

Authors:  Sheryl Zelenitsky; Robert Ariano; Godfrey Harding; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 7.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 8.  Setting and revising antibacterial susceptibility breakpoints.

Authors:  John Turnidge; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

9.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 10.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.